Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326774 | 0.93 | P2RY12 (0.65) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3326835 | 0.93 | P2RY12 (0.73) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3327261 | 0.92 | P2RY12 (0.72) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3326901 | 0.92 | P2RY12 (0.74) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3328638 | 0.90 | P2RY12 (0.84) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3328674 | 0.89 | P2RY12 (0.68) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3588756 | 0.89 | P2RY12 (0.70) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3326486 | 0.89 | P2RY12 (0.76) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3326950 | 0.89 | P2RY12 (0.74) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3589847 | 0.88 | P2RY12 (0.69) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | claimed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP2C9 114/4885CYP3A4 451/4885 |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP2C9 964/4885CYP3A4 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.